LLYELI LILLY AND COMPANY·OtherNeutral

Other · 2028-12-31

2028.12.31 · 10-Q · filed
aiSwingX™ analyzes US filings and reports them as news investors can read.
0 0

What happens

A dated fact the company wrote in its filing; see the original sentence.

From the filing

“For the Jardiance product family in the most significant markets, which remains in the collaboration through December 31, 2028, we receive a share of net sales depending on performance of the product, which we recognize as collaboration and other revenue”
The full sentence, translation and EDGAR link are shown to subscribers.
Subscribe

Analysis of this filing

Eli Lilly: 3% of U.S. revenue (about $430m) came from revising rebate estimates on earlier shipments — rebate liability $21.1bn, prices −3% in the U.S. and −36% abroad

Other dates in this filing

This page reproduces the date and sentence the company wrote in its filing. The tone label (positive/negative/neutral) is a rule-based classification by item type, not investment advice.

Frequently asked questions

How often are articles published?

Mostly during earnings season — an article for each covered company when its 10-Q or 10-K is filed, plus material 8-K filings when relevant.

Can I request a ticker?

Yes. Send a request through Messages after logging in and we will consider it for the next earnings season. License customers may nominate priority tickers.

What is on a ticker page?

The company's articles and a table of key metrics that accumulates quarter by quarter, so the same figure can be compared over time.

aiSwingX™ analyzes US filings and reports them as news investors can read.
0 0